Sagimet Biosciences Inc. (SGMT)

Market Cap	230.25M
Revenue (ttm)	n/a
Net Income (ttm)	-57.67M
Shares Out	32.52M
EPS (ttm)	-1.79
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	306,179
Open	7.00
Previous Close	6.98
Day's Range	6.92 - 7.15
52-Week Range	1.73 - 11.41
Beta	3.31
Analysts	Strong Buy
Price Target	29.75 (+320.2%)
Earnings Date	Nov 13, 2025

About SGMT

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company’s lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs, such as various solid tumor an...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 14, 2023
• Employees: 14
• Stock Exchange: NASDAQ
• Ticker Symbol: SGMT
• Website: https://www.sagimet.com

Analyst Summary

According to 8 analysts, the average rating for SGMT stock is "Strong Buy." The 12-month stock price target is $29.75, which is an increase of 320.20% from the latest price.

Price Target

$29.75

(320.20% upside)

Analyst Consensus: Strong Buy